Best Practice & Research Clinical Haematology
Volume 19, Issue 1 , Pages 113-126 , March 2006

Treating coagulopathy in liver disease with plasma transfusions or recombinant factor VIIa: an evidence-based review

  • Glenn Ramsey, MD (Associate Professor, Feinberg School of Medicine, Northwestern University, and Medical Director, Blood Bank, Northwestern Memorial Hospital, Chicago, Illinois, USA)

      Affiliations

    • Corresponding Author InformationTel.: +1 312 926 3082; Fax: +1 312 926 5500.

References 

  1. Filatov A, Kartasevskij N. Die transfusion von menschlichem blutplasma als blutstillendes mittel. Zentrallbl Chir. 1935;8:441–445
  2. Amitrano L, Guardascione MA, Brancaccio V, Balzano A. Coagulation disorders in liver disease. Semin Liver Dis. 2002;22:83–96
  3. Stansworth SJ, Brunskill SJ, Hyde CJ, et al. Is fresh frozen plasma clinically effective? A systematic review of randomized controlled trials. Br J Haematol. 2004;126:139–152
  4. British Committee for Standards in Haematology, Blood Transfusion Task Force . Guidelines for the use of fresh-frozen plasma, cryoprecipitate and cryosupernatant. Br J Haematol. 2004;126:11–28
  5. Gazzard BG, Henderson JM, Williams R. Early changes in coagulation following a paracetamol overdose and a controlled trial of fresh frozen plasma therapy. Gut. 1975;16:617–620
  6. Spector I, Corn M, Ticktin HE. Effect of plasma transfusions on the prothrombin time and clotting factors in liver disease. N Engl J Med. 1966;275:1032–1037
  7. Youssef WI, Salazar F, Dasarathy S, et al. Role of fresh frozen plasma infusion in correction of coagulopathy of chronic liver disease: a dual phase study. Am J Gastroenterol. 2003;98:1391–1394
  8. Consensus conference . National Institutes of Health. Fresh-frozen plasma: indications and risks. JAMA. 1985;253:551–553
  9. National Blood Resource Program Education Program Expert Panel . In: Transfusion Alert: Indications for the Use of Red Blood Cells, Platelets, and Fresh Frozen Plasma. Publication No. 93297a. Bethesda, MD: National Institutes of Health; 1993;
  10. Fresh-Frozen Plasma, Cryoprecipitate, and Platelets Administration Practice Guidelines Development Task Force . Practice parameter for the use of fresh frozen plasma, cryoprecipitate, and platelets. JAMA. 1994;271:777–781
  11. American Society of Anesthesiologists Task Force on Blood Component Therapy . Practice guidelines for blood component therapy. Anesthesiology. 1996;84:732–747
  12. Expert Working Group . Guidelines for red blood cell and plasma transfusion for adults and children. Can Med Assoc J. 1997;156(11 supplement):S1–S24
  13. Becker J, Blackall D, Evans C, et al. Guidelines for Blood Utilization Review. Bethesda, MD: American Association of Blood Banks; 2001;
  14. Cable R, Carlson B, Chambers L, et al. Practice guidelines for blood transfusion: a compilation from recent peer-reviewed literature. Washington, DC: American National Red Cross; 2002;
  15. British Committee for Standards in Haematology Transfusion Task Force . Transfusion guidelines for neonates and older children. Br J Haematol. 2004;124:433–453
  16. Dzik WH. Predicting hemorrhage using preoperative coagulation screening assays. Curr Hematol Rep. 2004;3:324–330
  17. Burns ER, Goldberg SN, Wenz B. Paradoxic effect of multiple mild coagulation factor deficiencies on the prothrombin time and activated partial thromboplastin time. Am J Clin Pathol. 1993;100:94–98
  18. Ghany M, Hoofnagle JH. Approach to the patient with liver disease. In:  Kasper DL,  Braunwald E,  Fauci AS, et al. editor. Harrison's Principles of Internal Medicine. 16th edn. New York: McGraw-Hill; 2005;p. 1808–1813
  19. MELD/PELD Calculator. Richmond, VA: United Network for Organ Sharing; 2004. Online. Available at: http://www.unos.org [accessed December 5, 2004].
  20. Liver organ sharing principles. Bristol: UK Transplant; 2003. Online. Available at: http://www.uktransplant.org [accessed November 21, 2004].
  21. Deitcher SR. Interpretation of the international normalised ratio in patients with liver disease. Lancet. 2002;359:47–48
  22. Kovacs M. International normalised ratio and liver impairment (letter). Lancet. 2002;359:1695
  23. Trotter JF, Brimhall B, Arjal R, Phillips C. Specific laboratory methodologies achieve higher model for endstage liver disease (MELD) scores for patients listed for liver transplantation. Liver Transpl. 2004;10:995–1000
  24. Freeman Jr. RB, Wiesner RH, Roberts JP, et al. Improving liver allocation: MELD and PELD. In 2003 Annual Report of the U.S. Organ Procurement and Transplantation Network and the Scientific Registry of Transplant Recipients: Transplant Data 1993–2002. p. X-4. Department of Health and Human Services, Rockville, MD; United Network for Organ Sharing, Richmond, VA; University Renal Research and Education Association, Ann Arbor, MI; 2003. Online. Available at: http://www.optn.org [accessed December 5, 2004].
  25. Toy P. Plasma transfusion and alternatives. In:  Simon TL,  Dzik WH,  Snyder EL, et al. editor. Rossi's Principles of Transfusion Medicine. 3rd edn. Philadelphia: Lippincott Williams and Wilkins; 2002;p. 335–340
  26. Piccinino F, Sagnelli E, Pasquale G, Giusti G. Complications following percutaneous liver biopsy. A multicentre retrospective study on 68,276 biopsies. J Hepatol. 1986;2:165–173
  27. McGill DB, Rakela J, Zinsmeister AR, Ott BJ. A 21-year experience with major hemorrhage after percutaneous liver biopsy. Gastroenterology. 1990;99:1396–1400
  28. Terjung B, Lemnitzer I, Dumoulin FL, et al. Bleeding complications after percutaneous liver biopsy. An analysis of risk factors. Digestion. 2003;67:138–143
  29. McVay PA, Toy PT. Lack of increased bleeding after liver biopsy in patients with mild hemostatic abnormalities. Am J Clin Pathol. 1990;94:747–753
  30. Grant A, Neuberger J. Guidelines on the use of liver biopsy in clinical practice. Gut. 1999;45(supplement IV):IV1–IV11
  31. Ewe K. Bleeding after liver biopsy does not correlate with indices of peripheral coagulation. Dig Dis Sci. 1981;26:388–393
  32. McVay PA, Toy PTCY. Lack of increased bleeding after paracentesis and thoracentesis in patients with mild coagulation abnormalities. Transfusion. 1991;31:164–171
  33. Fisher NC, Mutimer DJ. Central venous cannulation in patients with liver disease and coagulopathy—a prospective audit. Intensive Care Med. 1999;25:481–485
  34. Martin RCG, Jarnagin WR, Fong Y, et al. The use of fresh frozen plasma after major hepatic resection for colorectal metastasis: is there a standard for transfusion?. J Am Coll Surg. 2003;196:402–409
  35. Ramsey G. Transfusion therapy in solid-organ transplantation. In:  Simon TL,  Dzik WH,  Snyder EL, et al. editor. Rossi's Principles of Transfusion Medicine. 3rd edn. Philadelphia: Lippincott Williams and Wilkins; 2002;p. 622–631
  36. Laine E, Steadman R, Calhoun L, et al. Comparison of RBCs and FFP with whole blood during liver transplant surgery. Transfusion. 2003;43:322–327
  37. Singer AL, Olthoff KM, Kim H, et al. Role of plasmapheresis in the management of acute hepatic failure in children. Ann Surg. 2001;234:418–424
  38. Skerrett D, Mor E, Curtiss S, Mohandas K. Plasmapheresis in primary dysfunction of hepatic transplants. J Clin Apheresis. 1996;11:10–13
  39. Mandal AK, King KE, Humphreys SL, et al. Plasmapheresis: an effective therapy for primary allograft nonfunction after liver transplantation. Transplantation. 2000;70:216–220
  40. Lerner RG, Nelson J, Sorcia E, et al. Evaluation of solvent/detergent-treated plasma in patients with a prolonged prothrombin time. Vox Sang. 2000;79:161–167
  41. Williamson LM, Llewelyn CA, Fisher NC, et al. A randomized trial of solvent/detergent-treated and standard fresh-frozen plasma in the coagulopathy of liver disease and liver transplantation. Transfusion. 1999;39:1227–1234
  42. Leebeek FWG, Schipperus MR, van Vliet HHDM. Coagulation factor levels in solvent/detergent-treated plasma (letter). Transfusion. 1999;39:1150–1151
  43. Beeck H, Hellstern P. In vitro characterization of solvent/detergent-treated human plasma and of quarantine fresh frozen plasma. Vox Sang. 1998;74(supplement 1):219–223
  44. Sarode R, Yomtovian R, Williamson LM, Llewelyn CA. Efficacy of SD-treated plasma during liver transplantation (letter). Transfusion. 2000;40:886–888
  45. De Jonge J, Groenland THN, Metselaar HJ, et al. Fibrinolysis during liver transplantation is enhanced by using solvent/detergent virus-inactivated plasma (ESDEP®). Anesth Analg. 2002;94:1127–1131
  46. Ozier Y, Rieux C. Liver transplantation, solvent-detergent treated plasma and antifibrinolyics (letter). Anesth Analg. 2003;96:1231
  47. PLAS+SD (Pooled Plasma [Human] Solvent Detergent Treated): important prescribing information. Safety Information, Center for Biologics Evaluation and Research. Bethesda, MD: Food and Drug Administration. October 20, 2000. Online. Available at: http://www.fda.gov/cber [accessed December 5, 2004].
  48. Important new drug warning—PLAS+SD (Pooled Plasma, (Human) Solvent Detergent Treated). Safety Information, Center for Biologics Evaluation and Research. Bethesda, MD: Food and Drug Administration. March 29, 2002. Online. Available at: http://www.fda.gov/cber [accessed December 5, 2004].
  49. Solheim BG, Bergan A, Brosstad F, et al. Fibrinolysis during liver transplant and use of solvent/detergent virus-inactivated plasma (ESDEP®/Octaplas®). Anesth Analg. 2003;96:1230–1231
  50. Williamson LM, Cardigan R, Prowse CV. Methylene blue-treated fresh-frozen plasma: what is its contribution to blood safety?. Transfusion. 2003;43:1322–1329
  51. Atance R, Pereira A, Ramirez B. Transfusing methylene blue-photoinactivated plasma instead of FFP is associated with an increased demand for plasma and cryoprecipitate. Transfusion. 2001;41:1548–1552
  52. Mintz P, Steadman R, Blackall D, et al. Pathogen inactivation of plasma using S-59 and UVA light is efficacious and well tolerated in the treatment of end-stage liver disease patients-the STEP AC trial (abstract). Transfusion. 2002;42(supplement):15S
  53. Roberts HR, Monroe DM, White GC. The use of recombinant factor VIIa in the treatment of bleeding disorders. Blood. 2004;104:3858–3864
  54. Bosch J, Thabut D, Bendtsen F, et al. Recombinant factor VIIa for upper gastrointestinal bleeding in patients with cirrhosis: a randomized, double-blind trial. Gastroenterology. 2004;127:1123–1130
  55. Planinsic RM, Testa G, Emre S, et al. Safety and efficacy of single bolus dose of recombinant factor VIIa in patients undergoing orthotopic liver transplantation: a randomized multi-center study (abstract). Hepatology. 2002;36(4 Pt 2):660A
  56. Lodge P, Jonas S, Jaeck D, Fridberg MJ. Recombinant factor VIIa (NovoSeven®) in partial hepatectomy: a randomized, placebo-controlled, double-blind clinical trial (abstract). Hepatology. 2002;36(4 Pt 2):211A
  57. Lodge JPA. Hemostasis in liver resection surgery. Semin Hematol. 2004;41(supplement 1):70–75
  58. Shami VM, Caldwell SH, Hespenheide EE, et al. Recombinant activated factor VII for coagulopathy in fulminant hepatic failure compared with conventional therapy. Liver Transpl. 2003;9:138–143
  59. Jeffers L, Chalasani N, Balart L, et al. Safety and efficacy of recombinant factor VIIa in patients with liver disease undergoing laparoscopic liver biopsy. Gastroenterology. 2002;123:118–126
  60. Goodnough LT, Lublin DM, Zhang L, et al. Transfusion medicine service policies for recombinant factor VIIa administration. Transfusion. 2004;44:1325–1331

PII: S1521-6926(05)00048-4

doi: 10.1016/j.beha.2005.01.034

Best Practice & Research Clinical Haematology
Volume 19, Issue 1 , Pages 113-126 , March 2006

Article Tools